These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 26210957)
1. Evading innate immunity in nonviral mRNA delivery: don't shoot the messenger. Devoldere J; Dewitte H; De Smedt SC; Remaut K Drug Discov Today; 2016 Jan; 21(1):11-25. PubMed ID: 26210957 [TBL] [Abstract][Full Text] [Related]
2. Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems. Guan S; Rosenecker J Gene Ther; 2017 Mar; 24(3):133-143. PubMed ID: 28094775 [TBL] [Abstract][Full Text] [Related]
3. The Dual Role of the Innate Immune System in the Effectiveness of mRNA Therapeutics. Muslimov A; Tereshchenko V; Shevyrev D; Rogova A; Lepik K; Reshetnikov V; Ivanov R Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834268 [TBL] [Abstract][Full Text] [Related]
4. Strategies for controlling the innate immune activity of conventional and self-amplifying mRNA therapeutics: Getting the message across. Minnaert AK; Vanluchene H; Verbeke R; Lentacker I; De Smedt SC; Raemdonck K; Sanders NN; Remaut K Adv Drug Deliv Rev; 2021 Sep; 176():113900. PubMed ID: 34324884 [TBL] [Abstract][Full Text] [Related]
6. IVT-mRNA reprogramming of myeloid cells for cancer immunotherapy. Jolly KJ; Zhang F Adv Pharmacol; 2024; 100():247-288. PubMed ID: 39034054 [TBL] [Abstract][Full Text] [Related]
7. Delivering the right message: Challenges and opportunities in lipid nanoparticles-mediated modified mRNA therapeutics-An innate immune system standpoint. Granot Y; Peer D Semin Immunol; 2017 Dec; 34():68-77. PubMed ID: 28890238 [TBL] [Abstract][Full Text] [Related]
8. An in vitro-transcribed-mRNA polyepitope construct encoding 32 distinct HLA class I-restricted epitopes from CMV, EBV, and Influenza for use as a functional control in human immune monitoring studies. Nielsen JS; Wick DA; Tran E; Nelson BH; Webb JR J Immunol Methods; 2010 Aug; 360(1-2):149-56. PubMed ID: 20637775 [TBL] [Abstract][Full Text] [Related]
14. Enhancing Cancer Immunotherapy Via Activation of Innate Immunity. Goldberg JL; Sondel PM Semin Oncol; 2015 Aug; 42(4):562-72. PubMed ID: 26320061 [TBL] [Abstract][Full Text] [Related]
15. Chemical modifications on siRNAs avoid Toll-like-receptor-mediated activation of the hepatic immune system in vivo and in vitro. Broering R; Real CI; John MJ; Jahn-Hofmann K; Ickenstein LM; Kleinehr K; Paul A; Gibbert K; Dittmer U; Gerken G; Schlaak JF Int Immunol; 2014 Jan; 26(1):35-46. PubMed ID: 24065781 [TBL] [Abstract][Full Text] [Related]
16. Non-Immunotherapy Application of LNP-mRNA: Maximizing Efficacy and Safety. Vlatkovic I Biomedicines; 2021 May; 9(5):. PubMed ID: 34068715 [TBL] [Abstract][Full Text] [Related]
17. Therapeutic mRNA delivery to leukocytes. Granot-Matok Y; Kon E; Dammes N; Mechtinger G; Peer D J Control Release; 2019 Jul; 305():165-175. PubMed ID: 31121277 [TBL] [Abstract][Full Text] [Related]